PetMed Express, Inc. (NASDAQ:PETS) is a prominent player in the pet pharmacy industry, providing prescription and non-prescription pet medications and other health products for dogs, cats, and horses. The company operates primarily through its online platform, PetCareRx, and competes with other pet care giants like Chewy and Petco.
On August 26, 2025, PETS is set to release its quarterly earnings. Wall Street analysts predict an earnings per share (EPS) of -$0.06, indicating a potential loss for the quarter. Despite this, the company is expected to generate approximately $51.1 million in revenue, showcasing its ability to maintain sales even amidst financial challenges.
Recently, PetMed Express has undergone significant management changes. CEO Sandra Campos and CFO Robyn D'Elia have resigned, with Leslie C.G. Campbell stepping in as Interim CEO and Douglas Krulik as Interim Principal Financial Officer. The company is actively seeking permanent replacements for these key roles, as highlighted by the recent announcements.
Financially, PETS has a high price-to-earnings (P/E) ratio of 181.49, suggesting that investors are paying a premium for its earnings. However, its price-to-sales ratio of 0.26 indicates that the market values its sales at a lower rate. The enterprise value to sales ratio of 0.06 further reflects a low valuation compared to its sales.
The company's financial health is supported by a low debt-to-equity ratio of 0.01, indicating minimal leverage. Additionally, a current ratio of 1.43 suggests that PETS has sufficient liquidity to cover its short-term liabilities. Despite these strengths, the earnings yield of 0.55% points to a modest return on investment for shareholders.
